BioPorto A/S (BIOPOR.CO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Peter Moerch Eriksen B.B.A., BBA | Chief Executive Officer | 4.78M | -- | 1960 |
| Mr. Niels Hoey Nielsen | Executive VP & Group CFO | 2.41M | -- | 1970 |
| Ms. Gry Husby Larsen | Executive VP & Group Chief Legal Officer | 2.33M | -- | 1980 |
| Ms. Hanne Sogaard | Head of Investor Relations | -- | -- | -- |
| Ms. Jennifer Zonderman | Senior Vice President of Global Marketing & Commercialization | -- | -- | -- |
| Ms. Ursula Klause Ph.D. | Senior Vice President of Global Clinical & Technical Development | -- | -- | -- |
| Mr. Jeffrey N. Haas | President & CEO of BioPorto Inc. | -- | -- | -- |
BioPorto A/S
- Sector:
- Healthcare
- Industry: Diagnostics & Research
- Full Time Employees:
- 48
Description
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease. The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays. BioPorto A/S was founded in 1917 and is based in Hellerup, Denmark.
Corporate Governance
Upcoming Events
May 8, 2025 at 6:30 AM UTC
BioPorto A/S Earnings Date